Back to Journals Drug Design, Development and Therapy Volume 19 The Role of Radiosensitizing Drugs in Osteosarcoma Treatment: Mechanisms and Clinical Perspectives Authors Zhang Y, Xie Y, Wang Y, Huang P, Lu Y Received 16 December 2024 Accepted for publication 9 March 2025 Published 14 March 2025 Volume 2025:19 Pages 19271942 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Muzammal Hussain Yilei Zhang, * Yuhuan Xie, * Yiwen Wang, * Panpan Huang, Yao Lu School of Basic Medicine, Gannan Medical University, Ganzhou, Jiangxi, 341000, Peoples Republic of China *These authors contributed equally to this work Correspondence: Yao Lu
It is for electrolytes
A triple agonist peptide that targets GIP, GLP-1, and glucagon receptors
Early studies in women with PCOS suggest potential improvements in insulin sensitivity, hyperandrogenism, and menstrual cyclicity with glucagon-like peptide-1 receptor agonist therapy [14, 15], yet the reproductive safety and clinical impact of use before conception remain uncertain [16]
Patients eligible to enter the trial were 50 years of age or older and had established, stable, CV, cerebrovascular, peripheral artery disease, CKD or NYHA class II and III heart failure or were 60 years of age or older and had other specified risk factors for CV disease
For injectable products that go directly into your body, 503B facilities offer a higher baseline quality assurance standard